Dr. R. Katie Kelley is a gastrointestinal oncologist who specializes in hepatobiliary cancers, such as cholangiocarcinoma, hepatocellular carcinoma, and gall bladder cancer, as well as gastrointestinal cancers including gastric cancer, esophageal cancer, colon and rectal cancers, pancreatic cancer, and gastrointestinal stromal tumors. Her research focuses on developing clinical trials of novel therapeutic agents and treatment combinations in hepatocellular carcinoma and biliary tract cancers, closely integrated with translational research using tumor specimens from patients to identify novel biomarkers and therapeutic targets in these challenging cancers of the liver. She works closely with colleagues in surgical oncology, hepatology, interventional radiology, radiation oncology, and the liver transplant program at UCSF.
Dr. Kelley was born in Montana and grew up in San Diego, California. She received her undergraduate degree in biochemical sciences from Harvard University in 1997. She then completed her medical training at the UCLA School of Medicine in 2002, followed by residency in Internal Medicine at UCLA from 2002-2005, and chief residency in 2005-2006. She received her fellowship training in Hematology/Oncology at the University of California San Francisco from 2006-2009, joining faculty as an Assistant Professor of Medicine in 2010.
Since 2012, Dr. Kelley has also served as the Executive Officer for the Translational Research Program of the Alliance for Clinical Trials in Oncology, as part of the National Clinical Trials Network. She has been a member of the National Comprehensive Cancer Network (NCCN) Hepatobiliary Panel since 2010. She was a writing member of the NCCN Task Force on Clinical Utility of Cancer Biomarkers in 2011 and a junior member of the NCI Hepatobiliary Task Force from 2011-2012.
Dr. Kelley is an attending at UCSF for both the inpatient medical oncology consult service and outpatient gastrointestinal oncology clinical service.
Related Conditions and Treatments: